A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2019
Price : $35 *
At a glance
- Drugs Doxorubicin (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Therapeutic Use
- Acronyms CerebralEDV
- Sponsors EnGeneIC
- 31 Aug 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 14 Feb 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 14 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2019.